Exelixis, Inc. (EXEL): Price and Financial Metrics

Exelixis, Inc. (EXEL)

Today's Latest Price: $19.41 USD

0.68 (3.63%)

Updated Nov 27 1:00pm

Add EXEL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

EXEL Stock Summary

  • The ratio of debt to operating expenses for Exelixis Inc is higher than it is for about merely 9.07% of US stocks.
  • EXEL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 9.94% of US stocks.
  • With a year-over-year growth in debt of 100.91%, Exelixis Inc's debt growth rate surpasses 88.18% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Exelixis Inc, a group of peers worth examining would be GNTX, MYOV, CKPT, RARE, and HRTX.
  • EXEL's SEC filings can be seen here. And to visit Exelixis Inc's official web site, go to www.exelixis.com.

EXEL Stock Price Chart Interactive Chart >

Price chart for EXEL

EXEL Price/Volume Stats

Current price $19.41 52-week high $27.80
Prev. close $18.73 52-week low $13.67
Day low $18.52 Volume 1,739,955
Day high $19.47 Avg. volume 2,920,189
50-day MA $22.12 Dividend yield N/A
200-day MA $22.06 Market Cap 6.02B

Exelixis, Inc. (EXEL) Company Bio

Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.

EXEL Latest News Stream

Event/Time News Detail
Loading, please wait...

EXEL Latest Social Stream

Loading social stream, please wait...

View Full EXEL Social Stream

Latest EXEL News From Around the Web

Below are the latest news stories about Exelixis Inc that investors may wish to consider to help them evaluate EXEL as an investment opportunity.

Exelixis: Good News And Bad Plus Stubborn Stock Price Makes Investment Case Less Attractive

Investment Thesis I am revisiting Exelixis' (EXEL) investment case after 3 months. As expected, revenues have been flat so far in 2020, but slightly worryingly, sales volumes appear to be falling since the price of lead candidate Cabometyx has been raised, and OPEX is growing significantly. Cabometyx looks likely to...

Edmund Ingham on Seeking Alpha | September 28, 2020

Exelixis reports early-stage study results from cabozantinib/atezolizumab combo in solid tumors

Exelixis ([[EXEL]] -3.8%) has announced interim analysis from ongoing Phase 1b (COSMIC-021) trial of Cabometyx (cabozantinib) in combination with Roche' Tecentriq (atezolizumab), for the treatment of locally advanced or metastatic solid tumors. Data from two expansion cohorts was presented during the European Society for Medical Oncology Congress.Interim results from cohort 1 (clear cell...

Seeking Alpha | September 21, 2020

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study

Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday. The drug combination also doubled

Yahoo Finance | September 18, 2020

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study | Health

"There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston. He noted that the oncology community is already familiar with both drugs and that the combination demonstrated positive results on all the study's goals.

Devdiscourse | September 18, 2020

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that support the continued development of ICON-2, an ADC comprised of an anti-Tissue Factor (TF) antibody and Zymeworks’ proprietary linker-payload, for the treatment of diverse solid tumors. Exelixis has an exclusive option and license agreement for ICON-2 in oncology indications under its May 2019 agreement with Iconic Therapeutics, which d

Business Wire | September 15, 2020

Read More 'EXEL' Stories Here

EXEL Price Returns

1-mo -7.35%
3-mo -10.26%
6-mo -21.45%
1-year 17.14%
3-year -28.14%
5-year 254.84%
YTD 10.16%
2019 -10.42%
2018 -35.30%
2017 103.89%
2016 164.36%
2015 291.67%

Continue Researching EXEL

Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:

Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7233 seconds.